GlassScriptPhysician profile
David C Prendergast
NPI 1841256930
$3,096.56
in general payments reported to CMS, 2019-2025
31 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $106 · 2021: $408 · 2022: $771 · 2023: $311 · 2024: $571 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $568.81 | 2019-2025 | |
| Abbvie INC. | $487.37 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $199.22 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $175.09 | 2021-2022 | |
| Organon LLC | $149.61 | 2021-2024 | |
| Astellas Pharma US INC | $142.73 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $134.79 | 2019-2021 | |
| Olympus America INC. | $132.67 | 2019 | |
| Coopersurgical, INC. | $124.40 | 2020-2025 | Paragard T 380a, Cook |
| Dexcom, INC. | $84.02 | 2024-2025 | Dexcom G6 Transmitter |
| Aspira Women'S Health INC | $72.55 | 2022 | |
| Merck Sharp & Dohme LLC | $71.70 | 2019-2024 | Gardasil, Gardasil 9 |
| Hologic Sales and Service, LLC | $68.23 | 2019-2024 | Novasure, Acessa Provu System, Myosure Tissue Removal Device |
| Lilly USA, LLC | $65.45 | 2020-2024 | Zepbound |
| Minerva Surgical, INC | $64.04 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $61.84 | 2021-2022 | |
| Amgen INC. | $57.77 | 2019-2022 | |
| Novo Nordisk INC | $54.80 | 2021-2025 | |
| Conmed Corporation | $49.92 | 2025 | Airseal |
| Medtronic, INC. | $49.90 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $46.79 | 2025 | |
| Exeltis, USA INC. | $35.70 | 2021-2025 | Slynd |
| Intuitive Surgical, INC. | $34.37 | 2022 | |
| Allergan, INC. | $30.98 | 2019 | |
| Boston Scientific Corporation | $28.14 | 2019-2024 | Obtryx System - Curved |
| Pharmacosmos Therapeutics INC. | $22.80 | 2025 | Monoferric |
| Myriad Genetic Laboratories, INC. | $20.69 | 2024 | Myrisk |
| Biogen, INC. | $20.54 | 2024 | Zurzuvae |
| Therapeuticsmd, INC. | $18.34 | 2019 | |
| Duchesnay USA Incorporated | $11.68 | 2019 | |
| Lupin INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Prendergast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.